Navigation Links
Genesis Biopharma Adds Cell Therapy Bioprocess Engineering, Clinical Trial Design, Biostatistics, Regulatory Affairs and FDA Compliance Expertise
Date:9/19/2011

ic positions at Emory University, Duke University, University of Washington, Fred Hutchinson Cancer Research Center and Northwestern University, having taught numerous courses on clinical trial methodology and management, biostatistics and multivariate analysis, among others.  Dr. Blumenstein also has advised numerous companies including Dendreon Corporation on the design of clinical trials.  He has been a consultant to leading cancer centers including, St. Jude Children's Research Hospital, City of Hope, Massachusetts General Hospital, Pittsburg Cancer Institute and The Cleveland Clinic.  He is widely published and has participated as a reviewer for many prestigious journals.  He holds a B.S. in Chemistry and a Ph.D. in Biometry from Emory University.

Lizabeth J. Cardwell, MT (ASCP), MBA, RAC is an independent Quality Assurance and Regulatory Compliance consultant.  Ms. Cardwell has more than 25 years of experience in cGMP, GCP and QSR management at biotechnology and cell therapy companies.  Prior to forming her consultancy, she served as Director, Quality Assurance and Regulatory Affairs at Xcyte Therapies.  Previous to that, Ms. Cardwell was Vice President-Quality Assurance and Quality Control at Dendreon Corporation.  She also was Manager, Biologicals Manufacturing for Genetic Systems/Sanofi.  Ms. Cardwell holds an MBA in Quality Management from City University in Seattle, a Medical Technology Certification from Children's Orthopedic Hospital in Seattle and a Bachelor of Science in Biology from Pacific Lutheran University in Tacoma, Wash.

Carol A. Gloff, Ph.D. is Principal of Carol A. Gloff & Associates, a regulatory affairs, quality assurance and compliance, product development and pharmacokinetics consultancy.  Previously, Dr. Gloff was Vice President, Chief Regulatory Officer at ImmunoGen.  She also was with Alkermes, Inc., rising from Director of Product Development to Vic
'/>"/>

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
2. Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice
3. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
4. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
5. Cardiogenesis Announces Preliminary Clinical Results With the PHOENIX System Combining TMR + Stem Cells
6. Neuronascent, Inc. Receives Multiple Fundings for Its Neurogenesis Therapeutic Programs
7. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
8. ThermoGenesis Announces MXP Involvement in New Regenerative Medicine Initiatives
9. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
10. ThermoGenesis Announces National Institute of Health Grant
11. Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Cadence Fitness & Health Center ... by the Medical Fitness Association, a non-profit organization ... achieve their full potential. The Cadence Fitness & ... in the western suburbs and second in the ... Cadence Fitness & Health Center meets guidelines set ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ... as insulin delivery systems especially for type ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ... $2.92 per share, net to the seller in cash, ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... 7th Annual Healthcare Conference on Wednesday, November 17, 2010 at ... Interested parties may access a live webcast of the ... It is recommended that listeners log on 15 minutes early ...
... Watson Pharmaceuticals, Inc. (NYSE: WPI ) ... of its common stock held by Quiver, Inc. pursuant ... Securities and Exchange Commission (the "Offering") on August 17, ... common stock in connection with Watson,s acquisition of the ...
Cached Medicine Technology:Onyx Pharmaceuticals to Present at the Lazard Capital Markets 7th Annual Healthcare Conference 2Watson Announces Commencement of Secondary Offering by Selling Stockholder 2
(Date:4/14/2014)... North Therapeutics, Inc., announced today a publication demonstrating ... of human red blood cells exposed to plasma ... hemolytic anemia (AIHA). The article entitled "TNT003, an ... activation induced by cold agglutinin disease patient autoantibodies" ... earlier this month. TNT003 is the murine ...
(Date:4/14/2014)... April 14In dense, urban centers around the world, many ... surrounded by tall buildings that block sunlight. And as ... jammed closer together, the darkness will only spread. ... a corrugated, translucent panel that redirects sunlight onto narrow ... and hung over the edge at an angle, where ...
(Date:4/14/2014)... professor of chemical engineering at Virginia Tech , ... analyze living cells. The long-term goal is to gain ... In his lab , Lu and his students ... events inside cells. These devices promote high sensitivity and ... cells. , Based on their record of achievements, the ...
(Date:4/14/2014)... April 2014, Perth, Australia. Drug discovery company Proteomics ... development of a companion diagnostic (CDx) test with ... , The research team authenticated the panel of ... control samples. Seven biomarkers were validated at high ... , The mass spectrometry data was then cross-validated ...
(Date:4/14/2014)... guidelines for high-risk bladder cancer, chemotherapy before or ... clinical practice. The findings are published early online ... the American Cancer Society. , Clinical trials have ... muscle-invasive bladder cancer who are given chemotherapy before ... after surgery also improves survival. To investigate the ...
Breaking Medicine News(10 mins):Health News:Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2Health News:Efficient analysis of small quantity of cells improves chances to understand disease 2
... medication to treat kleptomania has failed to find any ... according to researchers at the Stanford University School of ... that some medications, including the one in the trial, ... ,More than 1.2 million people in the ...
... of acute lymphoblastic leukemia have a significantly increased risk ... // ,Acute lymphoblastic leukemia is the most common ... cases diagnosed in the United States each year. It ... survival rates for patients who receive contemporary treatments now ...
... pathway by which estradiol, the primary estrogen in humans ... aids in avoiding osteoporosis. // ,It is well ... that when the production of estrogen is reduced, as ... to radiation or chemotherapeutic drugs, bones become brittle and ...
... college students, could be as harmful as cigarettes, warns a ... water in a hookah, many youngsters feel that harmful agents ... have been found between water-pipe (hookah) usage and oral, lung ... arteries," it said quoting a report of the American Lung ...
... percentage of South Asians registered in the US National Marrow ... perforce join a long queue for matching donors. ... matching bone marrow transplant here. ,Urmi, 5, has ... transplant. She loves to play with her dolls and read ...
... cancer still remains the best way to ... During the 85th General Session of the International Association ... presented two novel, non-invasive, ultra-fast images approaches to oral ... than half of all oral cancer cases documented ...
Cached Medicine News:Health News:Study Finds No Conclusive Benefit from Treating Kleptomania 2Health News:Lymphoblastic Leukemia Survivors at Risk for Secondary Cancer 2Health News:Estradiol Guards Against Osteoporosis 2Health News:Novel Methods in Diagnosing Oral Cancer 2
... Reichert UNISTAT Bilirubinometer is ... for determining total bilirubin ... It quickly determines if ... needed by providing measurement ...
Anti-GBM IgG Assay...
... EIA Test is based on ... phase enzyme-linked immunosorbent assay. The ... anti-FSH for solid phase (microtiter ... FSH in the antibody-enzyme (horseradish ...
Enzyme immunoassay for the quantitative determination of IgG autoantibodies against type IV collagen of glomerular or alveolar basement membrane (GBM) in serum and plasma....
Medicine Products: